Stock Research for HZNP

HZNP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

HZNP Stock Chart & Research Data

The HZNP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the HZNP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


HZNP Due diligence Resources & Stock Charts

The HZNP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View HZNP Detailed Price Forecast - CNN Money CNN View HZNP Detailed Summary - Google Finance
Yahoo View HZNP Detailed Summary - Yahoo! Finance Zacks View HZNP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View HZNP Trends & Analysis - Trade-Ideas Barrons View HZNP Major Holders - Barrons
NASDAQ View HZNP Call Transcripts - NASDAQ Seeking View HZNP Breaking News & Analysis - Seeking Alpha
Spotlight View HZNP Annual Report - CompanySpotlight.com OTC Report View HZNP OTC Short Report - OTCShortReport.com
TradeKing View HZNP Fundamentals - TradeKing Charts View HZNP SEC Filings - Bar Chart
WSJ View Historical Prices for HZNP - The WSJ Morningstar View Performance/Total Return for HZNP - Morningstar
MarketWatch View the Analyst Estimates for HZNP - MarketWatch CNBC View the Earnings History for HZNP - CNBC
StockMarketWatch View the HZNP Earnings - StockMarketWatch MacroAxis View HZNP Buy or Sell Recommendations - MacroAxis
Bullish View the HZNP Bullish Patterns - American Bulls Short Pains View HZNP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View HZNP Stock Mentions - StockTwits PennyStocks View HZNP Stock Mentions - PennyStockTweets
Twitter View HZNP Stock Mentions - Twitter Invest Hub View HZNP Investment Forum News - Investor Hub
Yahoo View HZNP Stock Mentions - Yahoo! Message Board Seeking Alpha View HZNP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for HZNP - SECform4.com Insider Cow View Insider Transactions for HZNP - Insider Cow
CNBC View HZNP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for HZNP - OTC Markets
Yahoo View Insider Transactions for HZNP - Yahoo! Finance NASDAQ View Institutional Holdings for HZNP - NASDAQ


Stock Charts

FinViz View HZNP Stock Insight & Charts - FinViz.com StockCharts View HZNP Investment Charts - StockCharts.com
BarChart View HZNP Stock Overview & Charts - BarChart Trading View View HZNP User Generated Charts - Trading View




Latest Financial News for HZNP


Horizon Pharma (HZNP) Down 1.9% Since Last Earnings Report: Can It Rebound?
Posted on Friday September 07, 2018

Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Horizon Pharma Completes Enrollment in Eye Disease Study
Posted on Wednesday September 05, 2018

Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.


Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference
Posted on Tuesday September 04, 2018

Horizon Pharma plc announced today that the company will participate in the following conference:


Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
Posted on Tuesday September 04, 2018

Horizon Pharma plc (HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). Topline results are expected in the second quarter of 2019. “Our success in rapidly enrolling this trial speaks to the significant unmet need and the strong collaboration with Phase 3 study investigators,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “There is no FDA-approved therapy for TED, which can result in bulging of the eyes, known as proptosis, and cause additional challenges for those living with the disease.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.